Lipodepsipeptide antibiotic fusaricidin and its analogues. Total solid-phase and biological activity.
Infectious diseases due to antibiotic-resistant bacteria pose a serious threat to public health . The Centers for Disease Control and Prevention has estimated that nearly two million people a year in the U.S. develop nosocomial infections, and nearly 90,000 of those people die. For the past three decades the antibiotic vancomycin has been the last line of defense against bacterial strains that are resistant to most of antibiotics. However, the utility of this drug has been limited because of the emergence of vancomycin-resistant bacterial strains, most notably in enterococcal and staphylococcal nosocomial pathogens. Therefore, developing new antibiotics capable of treating infections from drug-resistant bacteria is of vital importance.
KeywordsHemolytic Activity Bacillus Polymyxa Lipid Tail Cyclic Depsipeptide Ester Bond Formation
This work was supported by NIH (1S06-GM073621-01) and AHA (0630175N) grants to P. Cudic.